Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Content from other channels on our network

Making cultivated meat more viable by re-using waste

WA-based Brownes Dairy is back on the market

New Chair of the Western Australian Meat Industry Authority Board

Top 6 impacts of robots, revealed in IFR position paper

What food-grade compressed air actually means

UNSW engineers awarded grant for critical renewables research

Australia–Japan laser a new step towards advanced defence manufacturing

Robots have a positive effect on employment and productivity: report

Hazer technology to be evaluated by major Japanese power utility

Researchers recover silver from end‍-‍of‍-‍life solar panels

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

Smart stormwater system removes harmful pollutants

Researchers create compact supercapacitor designed for reuse

ARRC Gold Coast calls for market certainty on plastics